

REVIEW ARTICLE

Artificial intelligence for dementia drug discovery and trials optimization

Thomas Doherty^{1,2} | Zhi Yao³ | Ahmad A.I. Khleifat⁴ | Hanz Tantiangco⁵ |
Stefano Tamburin⁶ | Chris Albertyn⁷ | Lokendra Thakur^{8,9,10} | David J. Llewellyn^{11,12} |
Neil P. Oxtoby¹³ | Ilianna Lourida¹¹ | for the Deep Dementia Phenotyping (DEMON)
Network | Janice M. Ranson¹¹ | James A. Duce¹⁴

¹Eisai Europe Ltd, Hatfield, UK²University of Westminster, London, UK³LifeArc, Stevenage, UK⁴Institute of Psychiatry, Psychology & Neuroscience, Department of Basic and Clinical Neuroscience, King's College London, London, UK⁵Information School, University of Sheffield, Sheffield, UK⁶University of Verona, Department of Neurosciences, Biomedicine & Movement Sciences, Verona, Italy⁷Department of Old Age Psychiatry, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK⁸Division of Genetics and Genomics, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA⁹Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA¹⁰Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA¹¹University of Exeter Medical School, Exeter, UK¹²Alan Turing Institute, London, UK¹³UCL Centre for Medical Image Computing, Department of Computer Science, University College London, London, UK¹⁴The ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK

Correspondence

Thomas Doherty, Eisai Europe Ltd, Hatfield, AL10 9SN, UK.

Email: thomas_doherty@eisai.net

James A. Duce, The ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0AH, UK.

Email: ducejames@gmail.com

Thomas Doherty and Zhi Yao are joint lead authors.

Janice M. Ranson and James A. Duce are joint senior authors.

Funding information

Alzheimer's Research UK and the Alan Turing Institute/Engineering and Physical Sciences Research Council, Grant/Award Number:

Abstract

Drug discovery and clinical trial design for dementia have historically been challenging. In part these challenges have arisen from patient heterogeneity, length of disease course, and the tractability of a target for the brain. Applying big data analytics and machine learning tools for drug discovery and utilizing them to inform successful clinical trial design has the potential to accelerate progress. Opportunities arise at multiple stages in the therapy pipeline and the growing availability of large medical data sets opens possibilities for big data analyses to answer key questions in clinical and therapeutic challenges. However, before this goal is reached, several challenges need to be overcome and only a multi-disciplinary approach can promote data-driven decision-making to its full potential. Herein we review the current state of machine learning applications to clinical trial design and drug discovery, while presenting opportunities and recommendations that can break down the barriers to implementation.

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2023 The Authors. *Alzheimer's & Dementia* published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

EP/N510129/1; National Institute for Health Research; National Health and Medical Research Council; National Institute on Aging/National Institutes of Health, Grant/Award Number: RF1AG055654; Alan Turing Institute/Engineering and Physical Sciences Research Council, Grant/Award Number: EP/N510129/1; ALS Association Milton Safenowitz Research Fellowship, Grant/Award Number: 22- PDF-609.DOI :10.52546/pc.gr.150909

KEYWORDS

Alzheimer's Disease, artificial intelligence, big data, clinical trials, dementia, drug discovery, machine learning

1 | INTRODUCTION

There is no cure for any form of dementia, and existing treatment options do little to curb clinical progression. Drug discovery and development processes involve many complex and lengthy steps—from identification and validation of a target in which to test a drug, identification of drug hits from a screening campaign, optimization of the lead hit, to phase I–IV clinical trials. Despite decades of effort in identifying suitable therapies, this process remains costly and time consuming, and it often has a very high attrition rate.¹ It is estimated that for one approved drug that the total discovery and development costs are over \$5.7 billion, with a total duration of on average 13.5 years.^{2–4} The National Institutes of Health estimates that 80%–90% of research projects fail before ever reaching human trials, whereas 95% of drugs entering human trials fail.⁵ Drug trials for dementia have been no exception. Over the past few decades, trials looking to modify disease processes within Alzheimer's disease (AD) have shown an even higher attrition rate and are littered with costly failures.⁶ This has occurred across all stages of the drug-development process, from safety signals seen at phase I, II, and III to an absence of positive primary endpoints seen in all but two recent pivotal trials.^{7,8} Nevertheless, these clinical trial data sets are incredibly rich and highly characterized and have the potential to inform future trial designs.

There are many potential causes of the high attrition rate in these clinical trials, but the likely primary contributor is cohort heterogeneity. The heterogeneity of neurodegenerative diseases (NDs) within clinical trials predicates differences in an individual's drug response, underlying disease pathology, length of disease course, and the trajectory of the decline, among other factors. When contemplating trial design and patient selection, a patient's stage of disease along with anticipated future decline are key factors for success.^{1,6,9} With trials lasting only around 18 months in diseases that typically span decades, matching the right subjects to the right compound at the right time is fundamental to clinical trial outcomes and can characterize past failures.⁹ By refining patient selection and homogenizing a patient's disease proteinopathies, there is an increased likelihood of an efficacious outcome and subsequent regulatory approval, all of which is achieved through reduction in erroneous patient-level responses to a given therapy.

Traditionally drug hunters have preferred targeted chemical libraries and hypotheses around refined supportive evidence. The growing availability of large multi-omics data sets comprising tissue

samples from a broad range of patients, in combination with clinical data, provides a unique opportunity to generate biological hypotheses in the human population for individual- and group-level targeted therapies for all types of dementia.¹⁰

To aid these desired outcomes, there is an increasing realization and growing consensus of the potential in using big data analytics and machine learning (ML) tools for drug discovery and optimized clinical trials.^{10,11} There has been a near exponential growth in the application of these methods being used within this field, as shown by Figure 1.

As part of a series that covers a broad range of aspects on artificial intelligence (AI) for NDs, this review discusses the challenges that need to be overcome before this powerful approach can be fully harnessed in drug discovery and clinical trial optimization, including data standardization, reproducibility between groups, and translatability between experimental models and humans. We provide a multi-disciplinary view of current developments in the use of data science and AI at each stage of the drug discovery process: target discovery and drug design, development, and repurposing. We identify three key areas in which the use of data science and AI shows promise: predicting success, patient stratification, and informing clinical trial design. Finally, we provide recommendations on how a coordinated effort from biotechnology companies, academia, regulators, and health care professionals can drive progress. International research communities such as the Deep Dementia Phenotyping (DEMON) Network (www.demon dementia.com) provide a platform for innovation to help bridge these scientific fields and utilize focused working groups that best exploit what each area can offer to better inform both clinical trials and drug discovery.

2 | BIG DATA AND MACHINE LEARNING IN TARGET DISCOVERY AND PRIORITIZATION

The challenges in developing novel therapeutics for dementia and other NDs result from the paucity of novel, valid targets. This in turn results from etiological heterogeneity, the multifaceted, often polygenic nature of genetic risk and the complexity of the human brain.^{12,13} A recent study has found that drug targets with genetic support were twice as likely to improve approval likelihood of a new drug candidate at early-stage clinical trials.¹⁴ The discovery of genetic variants associated with the risk for neurological and neuropsychiatric illness provides the opportunity to significantly enhance hypothesis-




FIGURE 1 PubMed citations by year across Alzheimer's disease, dementias utilizing machine learning or artificial intelligence methodologies.

led drug discovery. Outside of NDs, this has been exemplified by high-risk mutations in PCSK9, leading to a specific target for lowering cholesterol being identified. Subsequent identification of individuals with knockout mutations and benign lower low-density lipoprotein (LDL) cholesterol has led to successful results in pivotal trials in the development of both evolocumab and alirocumab as treatment for hyperlipidemia.^{15,16} A recent study in schizophrenia utilized network analyses on genome-wide association study (GWAS) loci and rare variation data to identify biological pathways and mechanisms in NDs, via a combination of statistical genetic analysis approaches with chemoinformatic databases, and successfully identify potential new drugs and drug targets.¹⁷

With recent advances in the data science and ML field in the last decade, both academia and pharmaceutical companies have begun implementing these approaches within their early drug discovery process. The advances in genomic, transcriptomic, and proteomic technologies, combined with the accumulation of patient and disease relevant big data sets, have also promoted analytics and ML approaches for target identification. In an early study, Zhang and colleagues¹⁸ used integrative network-based analysis to interrogate gene expression data from post-mortem brain tissue samples. By rank-order network structures for relevance to late-onset AD pathology, the authors highlighted an immune and microglia-specific module dominated by genes involved in pathogen phagocytosis. Transmembrane immune signalling adaptor TYROBP was also found to be a key regulator of several microglial-specific genes highly expressed in AD brains and a potential therapeutic target for late-onset AD. A genome-wide AD-associated gene was recently identified using a support vector machine (SVM)-based approach that integrated gene expression data with human brain-specific gene network data.¹⁹ Further to this, network analysis with peptides and/or mRNA transcripts have already been used to identify additional potential AD targets.^{20,21} The combination of a high-dimensional genome-wide protein-protein interaction network with a deep learning-based computational framework, has also allowed drug-target prioritization and identification of potential repositionable drugs for AD.²² Although still in its infancy, feature

RESEARCH IN CONTEXT

- 1. Narrative Review:** The authors reviewed the literature using traditional (e.g., PubMed, Google Scholar) sources, meeting abstracts, regulatory guidance documents, and online articles. The authors have sought to have a broad review across many neurodegenerative disorders, with a particular focus on dementias and, in particular, Alzheimer's disease (AD).
- 2. Interpretation:** Our review suggests that although artificial intelligence (AI) and machine learning (ML) methods are increasing in their usage, with positive outcomes and findings, further application to drug development and clinical trials can be improved with more widespread knowledge of how to apply them as well as strong consensus guidelines on their implementation, thus allowing for a reduction of risk associated with new methodologies within clinical development.
- 3. Future Directions:** This article proposes suggestions on how greater adoption may be achieved across biotechnology companies, the wider pharmaceutical industry, and academia, as well as general health care settings.

extraction from published literature using semantic searching or natural language processing (NLP) has started to be explored in target discovery. IBM's Watson was initially used to help identify additional RNA-binding proteins that were subsequently validated by wet lab experiments and has provided some potential novel targets for NDs.²³

3 | BIG DATA AND MACHINE LEARNING IN DRUG DESIGN AND DEVELOPMENT

Virtual screening using ML is an important tool in the drug-development process. It has the capacity to increase the yields of potential drugs by conducting *in silico* searches over millions of compounds.²⁴ The main ML algorithms that can be used in this context are Bayesian, SVM, supervised learning, dimensionality reduction, artificial neural networks, and ensemble algorithms. The Bayesian learning algorithms include naive Bayes, semi-naive Bayes, as well as Bayesian networks (e.g., hidden Markov modeling) and represent input data as feature vectors to plot them in space with the same dimensionality. SVM algorithms construct an optimal hyperplane that dichotomizes the data points. Supervised learning algorithms include instance-based methods, decision tree algorithms, and distributed networks. Dimensionality reduction algorithms, such as principal component analysis and linear discriminant analysis, are used to reduce the number of variables by mapping data into a lower dimensional space and can be split into feature selection and feature extraction. Artificial neural networks are composed of nodes layered together to process input data in a

process known as forward propagation. Typically, forward propagation involves linear transformations and activation functions to process a given information. Deep neural networks are artificial neural networks with many layers and include recurrent neural networks, variational autoencoders, and generative adversarial networks.

Bayesian learning algorithms are some of the most common methodologies utilized in ML analyses. This has been employed to examine the biological activities of small molecules to prioritize them for experimental screening for AD²⁵ and predict active molecules against key targets for AD and Parkinson's disease (PD) using the multitarget-quantitative structure-activity relationships method.^{26–28} A Bayesian ML virtual screen of a large library of U.S. Food and Drug Administration (FDA)-approved drugs and clinical candidates also successfully identified several Gylcogen synthase kinase-3 β (GSK3 β) inhibitors.²⁹ Most recently, Google DeepMind has revolutionized the field with AlphaFold, enabling the prediction of three-dimensional (3D) protein structure from their amino acid sequences, allowing for easier and faster determination of target protein 3D structures, a critical step in drug design.³⁰

The application of ML is not limited only to small molecule-based drug design and development. With monoclonal antibody therapeutics becoming an increasingly popular approach to tackle traditionally difficult targets, ML techniques have also started to be applied to antibody design and optimization. In addition to 3D structure prediction from protein sequences, ML has been applied successfully to antibody-antigen interaction prediction and affinity maturation, often directly from antibody sequences.^{31–33} Recently, a deep neural network model was trained on a relatively small library (about 1×10^4 variants) that was based on the sequence alone of the therapeutic antibody trastuzumab to accurately predict antigen specificity.³² Such ML approaches could allow *in silico* testing of a large number of antibody sequences and significantly reduce both the financial and time costs of therapeutic antibody lead optimization.

4 | BIG DATA AND MACHINE LEARNING IN DRUG REPURPOSING

Big data and ML have also started to play a useful role in drug-repurposing opportunities. A network-based ML algorithm has been used to identify several existing drugs of potential use for vascular dementia,³⁴ and a disease network model has been proposed to repurpose drugs for use across dementias.³⁵ A study that explored various ML approaches/algorithms indicated that random forest was the best model for the prediction of AD drugs and targets.³⁶ More recently, Rodriguez et al.³⁷ developed an ML framework to evaluate the association between AD severity in neuropathology (determined by Braak stage) and a molecular mechanism based on gene expression data from human neuronal cell culture models. Although still requiring further validation within *in vitro* and *in vivo* efficacy models, the authors suggest that this offers a potential method for nominating candidates for drug repurposing. The potential utilization of big data analytics and ML tools with real world data in drug discovery and development also

comes with many challenges, such as nonstandard data, reproducibility between labs, and translatability between experiment models and humans.

5 | MACHINE LEARNING IN PREDICTING SUCCESS THROUGH DEVELOPMENT

The termination or withdrawal of a drug candidate has been due primarily due to two factors: lack of efficacy and unfavorable toxicity properties. Although some drug-likeness measures, such as Lipinski's Rule of 5,³⁸ Veber's Rule,³⁹ and Ghose's Rule,⁴⁰ have proved a useful guide for filtering out toxic compounds, their predictions are very conservative. Using an ML-based approach to analyze existing clinical trial data may prove to be a more data-driven approach to solve this problem and help design and progress drugs with less toxicity. Using a set of FDA-approved drugs and drugs that failed in clinical trials due to toxicity, a random forest model has been developed to combine both chemical properties and drug-likeness measurements with target properties (such as tissue-specific expression levels and network connectivity) to predict the likelihood of toxic events in independent test sets.⁴¹ Currently prediction models focus primarily on small molecular drugs, but with the development and curation of both experimental and clinical data from other modalities, such as antibodies and biological therapeutics, the same big data and ML-driven approaches could contribute to their preclinical development.

In terms of clinical trials failures due to lack of efficacy, poor translation between preclinical models and humans is one plausible cause. Some studies have begun using ML approaches to bridge the translational gap across species and are attempting to generate humanized computational models from animal models.⁴² Most studies use genomic and transcriptomic data from population studies and focus on cross-species pairs as well as genotype-phenotype relationships. One may hypothesize that using ML-based approaches to interrogate clinical trial data (especially individual level clinical data) along with preclinical experimental data, could shine a light on the translatability of experimental models and the development of computational models to predict the likelihood of success in clinical trials from animal experiment data.

6 | DATA SCIENCE IN PATIENT STRATIFICATION

NDs have distinct clinical signs and symptoms that define their diagnostic criteria. NDs, however, share a few crucial aspects. All NDs are characterized by aggregation of a specific protein product, the selective degeneration of a population of neurons, usual adult onset of disease, and heterogeneous etiology.^{43,44} Although 10%–20% of patients have a relevant family history, in most cases the condition appears sporadic. The estimated heritability of genetically complex NDs is between 40% and 80%.^{12,45}

Current classification of most NDs is based on clinical phenotypes, which often does not consider either underlying disease heterogene-

ity or overlapping disease mechanisms, thus hindering therapy tailoring due to the unknown links between mechanism and phenotype. Perhaps NDs should be considered as several different conditions that may look the same. For example, AD pathology causes dementia but is influenced by many variations in an individual's genetic profile, which can be argued to precipitate disease trajectory and result in subtle pathological variations. This leads to the argument that patient selection and stratification should take these considerations into account to find the patients at the right pathological stage/trajectory of AD. This is in line with the recently suggested probabilistic hypothetical model of AD suggested by Frisoni and colleagues.⁴⁶

These shared phenomena raise the possibility that NDs share pathogenic mechanisms. Indeed, there is increasing recognition of heterogeneity within and overlap between clinically defined ND entities.^{47–49} This has limited the success of effective drug development and clinical trials. There is an urgent need to now move beyond clinical phenotyping to recognize the presence of shared biological pathways across NDs. Stratifying patients into subgroups based on biological factors might help in predicting a patient's response. For example, in amyotrophic lateral sclerosis (ALS) more than 15% of patients have features of frontotemporal dementia (FTD) and detailed testing reveals that $\approx 50\%$ have cognitive and behavioral changes consistent with FTD.²⁰ Despite these commonalities, clinical phenotypes manifest via divergent pathology through selective neuronal vulnerability. Furthermore, there is a strong shared genetic component.^{50,51} *VCP*, *ERRB4*, and *C9orf72* are known to be associated with AD, ALS, and FTD; yet not all individuals who are at genetic risk of AD or FTD-ALS go on to develop the disease.

Personalized medicine approaches are more likely to result in effective treatments if they target the underlying causes directly. Such personalized approaches are exemplified by gene therapy. The benefit of using genetic information has been demonstrated clearly in oncology with breast cancer, that is, herceptin for women with HER-2-positive breast cancer, ovarian cancer, and colorectal cancer.^{52,53} For example, AD pathology causes dementia but is influenced by many variations in an individual's genetic profile, which might be useful in predicting disease trajectories and understanding the subtle disease variations.⁵⁴ Many genetic and multi-omic data sets of different NDs have been generated, and the availability of many new analytical tools are now for the first time allowing the combination of these resources to inform clinical trial design.^{55,56} The identification of biologically meaningful clusters using genetic or multi-omic data might allow for better stratification and patient selection with more targeted treatments due to a greater understanding of disease mechanisms.⁵⁷

Designing trials aimed at those expected to respond has the potential to be beneficial for all stakeholders. However, any ML-based approaches to screening/trial design would only be one step in the larger screening process to enable better clinical trials and should be implemented only while in discussion with the relevant regulatory authorities. As with all trial design, there is a balance to be found between the studied population (inclusion/exclusion criteria) and the target label designation. In relation to when a smaller population may be a barrier for FDA approval, the recently approved

QALSODY™ (tofersen)⁵⁸ for ALS patients carrying a superoxide dismutase 1 mutation provides a good example of successfully targeting a selected subpopulation (in this case $\approx 2\%$ ALS population).⁵⁹ Specifically, across the AD continuum the progressive pathology and differential rates of decline in biomarkers⁶⁰ necessitates a more nuanced approach to clinical trial design across all phases of drug development. Adaptive design is one avenue that has shown real promise when applied in phase II clinical trials. A recent application of ML methodologies for optimum dose selection allowed a quicker decision-making process in the development of Lecanemab. Subjects in the phase II study were assigned to the most likely beneficial dose using a Bayesian adaptive approach resulting in more subjects exposed to the most likely beneficial dose.⁶¹ This shortened timelines and allowed for a greater sample size in the most efficacious drug group. Deploying similar methodologies within concordant scenarios has the power to benefit subjects and researchers alike.

7 | CLINICAL TRIAL DESIGN AND MACHINE LEARNING

As described earlier, disease and pathology comorbidities are common within the general elderly population.⁶² Image analysis of these comorbidities lends itself to ML methodologies, and one example of this is the Subtype and Stage Inference (SuStain) algorithm.⁶³ This data driven (unsupervised) approach was designed to be able to identify any potential subgroups or progression patterns within cross-sectional databases across dementia types. This has been used within AD in the analysis of tau positron emission tomography (PET) images to uncover four distinct trajectories of deposition.⁶⁴ A recent study has also showing three optimal distinct amyloid accumulation subtypes, with each showing separate risk factors known to influence AD progression.⁶⁵ This further emphasizes the heterogeneity of AD, something that is common even within clinical trial cohorts aimed at a singular disease or process. Despite this, trials for diseases such as AD have populations that often display heterogeneous biomarker profiles, which suggests the presence of multiple stages or subtypes of disease.

Disentangling the heterogeneity of NDs such as AD is critical to get the right disease-modifying drugs to the right patients, at the right time—including during clinical trials. Recent evidence has shown indications of AD heterogeneity through a conceptual framework referred to as the ATX(N) continuum, which categorizes individuals using biomarkers that chart core AD pathophysiological features, namely, amyloid beta $A\beta$ (A), tau (T), neurodegeneration (N), and where X represents additional candidate biomarkers such as neuroimmune dysregulation, synaptic dysfunction, and blood–brain barrier alterations.^{66,67} Recent work from multiple groups proposes distinct subtypes of AD and were yielded from ML methodologies on RNA datapoints.^{68,69} Further evidence comes from a recent review of biological heterogeneity in AD,⁶² which concluded that there are three distinct drivers of heterogeneity including risk factors, protective factors, and concomitant non-AD pathology, all of which need to be addressed within clinical trial populations to better address the underlying disease process.

Further to this, prior phase trials can yield important information that informs a go or no-go decision. As outlined in Wessels et al.,⁷⁰ prior cognitive data as well as biomarker outputs can fundamentally drive future development. However, endpoints are sometimes underutilized or hypotheses poorly designed, leading to a discordance in findings across each phase of development. ML can play a key role in improving these decisions, trial design, and boosting the power of trials. This can be achieved by assisting trial enrichment with appropriate subjects classified prior to enrolment through imaging, cognitive trajectory (when measured over time), and subject stratifications.⁷¹⁻⁷³ Enriching cohorts with subjects who are at the correct stage for each individual compound can be achieved by fundamentally categorizing based upon biomarkers that relate to homogenous staging and prospective endpoint declines. Many markers now exist for accurate classification of subjects within the ATX(N) criteria for AD, nearly all of which are already captured within clinical trials. Similar criteria are now being implemented with other NDs with stratification by neurofilament light (NfL) allowing for clinical subtype dichotomization for PD,⁷⁴ which also holds promise for FTD, ALS, and dementia with Lewy bodies (DLB).

With regulatory approaches aligning with this narrative, part of the recent recommendations from the FDA⁷⁵ looked at three key areas to improve and enrich clinical trials: strategies to decrease variability, prognostic enrichment strategies, and predictive enrichment strategies. It is important to note that minimizing variability by excluding subjects who had large changes to patient-reported outcome measures at baseline, in essence placebo responders, is fundamental to this. However, instead of incorporating long lead times as well as additional endpoints and analyses, modeling progression based upon disease-specific biomarkers and sub-setting the analysis a priori can alleviate these operational constraints. Further to this, as biofluid markers become more accessible and cost-effective in larger trials, algorithms that can predict biomarker status become particularly useful in increasing screening success rates and could lead to quicker trials and speedier decisions on compound efficacy.

Given that these problems also exist outside of the common NDs, considering these other heterogenous areas for ways to improve clinical trial designs can also suggest possible benefits. The rare autosomal dominant mitochondrial disease Friedreich's ataxia has a number of concordant issues with which to contend and thus utilizing a single endpoint for trial outcomes is not ideal. It has instead been suggested to stratify by subtype to reduce the number of participants needed, match a subgroup to candidate compounds for yielding better results, and promote international collaboration as well as remote assessments and screenings to increase patient-selection speed.⁷⁶

Another example of enrichment comes from recent clinical trials with PD. When targeting people with early motor dysfunction, participants without a deficit in dopamine levels (as measured by single-photon emission computed tomography [SPECT]) can be excluded to enrich clinical trial populations with patients with idiopathic PD. This can improve the statistical power by excluding subjects who are unlikely to progress clinically. Reduced binding on this imaging modality has been shown to predict faster decline on the Unified Parkinson's Disease Rating Scale (UPDRS) parts II (activities of daily living) and III (motor examination).¹³ The European Medicines Agency issued

a full qualification opinion for the use of dopamine transporter as an enrichment biomarker in PD trials targeting subjects with early motor symptoms, indicating the applicability and utilization of these methodologies to clinical trials.⁷⁷

8 | LIMITATIONS OF ARTIFICIAL INTELLIGENCE FOR DRUG DISCOVERY

Several limitations are hampering progress in the application of AI to drug discovery. ML approaches are all dependent on the availability of high-quality, representative, unbiased, and rich labeled data that adequately capture the problem parameters required. For many drug targets there is now a huge amount of relevant chemical and biological information available, although much of these data are not machine readable or meaningfully combined. Expert curation, data wrangling, and domain expertise are needed to integrate data from multiple sources in an optimal way. Commercial considerations have been limited historically to the sharing of carefully guarded proprietary drug development data by pharmaceutical companies and publishers,⁷⁸ thus restricting data integration and progress. However, open science approaches to drug development have been trialed although remain rare, for example, the development of antimalarials by Eli Lilly using a crowdsourcing platform for compound screening.⁷⁹

Not all ML methods are equally explainable or practical to implement. Although ML methods such as SVMs and random forest have long been used in drug discovery, deep neural networks have recently risen to prominence due to their flexible architectures and ability to model complex interactions. However, they have also drawn criticism for their need for huge amounts of high-quality training data, lack of explainability, and hidden "black box" structure, raising concerns about their appropriateness in medicine development.⁸⁰ Furthermore, standard ML methods provide predictions and model associations without necessarily giving biologically grounded causal insights. Causal ML approaches are, therefore, being developed in an attempt to bridge the gap between prediction and explanation, although are not yet widely adopted.⁸¹ Finally, the more complicated the ML model, the greater the degree of expertise required for their development and optimization. Therefore, requirement for expert users remains another important limitation. In short, ML is not the magical panacea that it is sometimes portrayed to be. Taken together these limitations remind us that the effective application of ML to drug discovery remains heavily reliant upon human insight and expertise.

9 | KEY RECOMMENDATIONS IN USING DATA SCIENCE TO IMPROVE MEDICAL CARE FOR PATIENTS

9.1 | A biotech industry perspective

One of the main bottlenecks in applying big data analytics and ML to dementia drug discovery, or any drug discovery program, is the paucity of high-quality, clinically relevant, and well-annotated data

sets. In order to maximize the impact big data and ML can bring to drug discovery and eventually the patient, there is a need for sharing data in an open, non-competitive manner with multiple parties in the health care ecosystem. Some initiatives have started to make progress on this. TransCelerate from Biopharma Inc. enables the sharing of de-identified clinical data collected historically in the control arms of clinical trials with the aim of providing a better understanding of disease, improved patient stratification, and the generation of synthetic control arms.⁸² An oncology focused initiative, Project Data Sphere, has set a precedent for open-access data sharing, with a platform of patient-level clinical trials data from industry and academia, with many major pharmaceutical companies contributing data (<https://www.projectdatasphere.org>). With some dementia-focused data sharing initiatives, such as the Alzheimer's Disease Data Initiative (ADDI; <https://www.alzheimersdata.org/>), Critical Path Institute (CPI; <https://c-path.org/>), and the Global Alzheimer's Association Interactive Network (GAIN; <http://gain.org>) becoming more prominent, there is still a big need for more collaboration and data contributions from industry as well as academia and government agencies. This would help to deliver a better understanding of disease pathology and more efficient drug development.

In addition to closer collaboration between biotech, pharmaceutical companies, and academia within the biomedical sector, a wide interdisciplinary collaboration between different sectors, such as information technology companies, is crucial for maximizing the potential impact of big data and ML. With the rapid development of new AI and ML technologies, it is important for the biotech industry to embed computer science experts at an early stage into relevant initiatives in order to build core capabilities and interdisciplinary teams, as well as to leverage advisors from academic research groups with the necessary experience. This will not only help maximize the utilization of historical data, but, more importantly, will help to streamline current drug development timeframes by engaging with relevant ML and computational experts from the outset of a project. To this end, a number of biomedical-focused AI companies have emerged in recent years with collaborations between those AI companies and industry/academia proving fruitful. An example of this is Trials.ai working with Moores Cancer Center to manage their clinical trials and reportedly cutting the study's timeframe by $\approx 33\%$ while reducing data errors by 20% (www.pharma-iq.com).

9.2 | An academic perspective

Given their complexity and portrayal in popular culture, AI applications are particularly susceptible to public mistrust and misinterpretation. Academia offers an independent, rigorous, and objective pathway to assess the validity and reliability of AI in health care and clinical research. We argue that this is particularly important when applied to drug discovery and clinical trials in dementia, where the stakes of finding novel therapeutics are considerable and successful uptake and trust in breakthroughs are essential.

Primary activities in the academic sphere relate to development initiatives including the latest biomarkers and analysis methods.^{83,84} When combined, these can result in instrumental studies that redefine our understanding of disease progression and the underlying biology.^{47,64,85} Such discoveries promise high impact on clinical trials through enrichment and screening processes, as well as patient management in health care. However, they rely on collaborative efforts with biotech (for trials data access), regulators (compliance for implementation in clinical trials), and health care (for data and patient access). Large collaborative networks like the DEMON Network are vital to this, as they span all three sectors.

Taken literally, part of academia's primary purpose is to be an "academy" to train the future workforce to meet the needs of society. Training a data science literate workforce is urgently needed to meet the increasing move toward data-driven translational precision medicine.^{86,87} Academia also has the flexibility to take greater risks, due to having fewer constraints or less influence from external market forces. Once breakthroughs are made, academic-industry partnerships are crucial to implement and translate the innovation into real world settings.

9.3 | A health care perspective on utilization of these methodologies

The intersection of data science and health care has two key roles in drug development for dementia. First, data science can contribute to data-driven clinical decision support systems (CDSSs), which are essential because the multitude of data available to health care practitioners defies qualitative assessment.⁸⁸ Second, dementia trials are moving increasingly from symptomatic trials toward disease-modifying secondary prevention,⁸⁸ and in the future, perhaps even within primary prevention trials such as AHEAD 3-45.⁸⁹ Both will ultimately require linking with health care data to facilitate/support model training (e.g., CDSSs) and trial recruitment, which may be done primarily via electronic medical records (eMRs). This should be a focus in the near future for assisting with maximizing the information obtained in clinical studies as well as trial accuracy and success. AI will help clarify and harmonize data entry, analysis, and interpretation, which is required for analysis of eMRs outside of health care settings.

Finally, as many of the workforce are employed in both health care and academia, a close relationship will be of benefit. Clinical academics are crucial to ensuring innovations are evidence-based, but also have a realistic chance of being successfully adopted in practice and essential in providing a perspective throughout the clinical trials pipeline.

9.4 | A regulatory agencies perspective

Key to the successful implementation of these techniques into real world clinical trials is the alignment and guidance of regulatory agencies. Both EU and US stakeholders and regulators have issued

guidance and ethical considerations around ML and AI paradigms as well as position papers on clinical trial designs implementing ML methodologies.^{76,90-93} These papers have set out approaches but do not provide clear guidelines for wider applicability to clinical trials across all therapeutic areas.

One key principle needed from regulatory authorities is to harmonize their efforts in standardization. To do this there needs to be a set of principles, akin to Good Clinical Research Practice (GCP), for these types of paradigms. The FDA has begun to encourage the harmonization of Good ML Practice (GMLP), to describe a set of AI/ML best practices (e.g., data management, feature extraction, training, interpretability, evaluation, and documentation) but have yet to publish a full position paper on this topic. A number of groups have been working toward these guidelines in conjunction with regulators including Institute of Electrical & Electronics Engineers (IEEE), Association for the Advancement of Medical Instrumentation (AAMI), and International Medical Device Regulators Forum (IMDRF). Similarly, the European Medicines Agency (EMA) 2025 strategic document⁹³ outlines their plans to establish similar guidelines as well as acceptability metrics and success factor for approval of these paradigms. It is notable that they have also pledged to standardize with other regulatory agencies such as the FDA.

Current regulatory papers lag the wider usage of ML techniques, leading to regulatory uncertainty with risks for stakeholders and companies looking to implement these methodologies. Several groups have set out their own guidelines.⁹⁴⁻⁹⁶ However, without regulatory guidelines in place there will be inherent hesitancy from industry partners to implement these paradigms. This is largely because without prior knowledge of the levels of sensitivity and specificity in these new ML techniques, using GMLP and data governance principles (among others) that require approval, no drug development program would include these at risk. Nevertheless, the regulatory outlook from both the FDA and EMA is a positive forward-looking perspective. The appli-

cation of AI/ML to clinical trials methodology has already shown promise, but compliance guidance from these agencies is needed before ML techniques can be deployed in drug development.

10 | CONCLUSION AND FUTURE DIRECTIONS

There is ample scope for ML techniques to yield significant contributions across drug discovery and clinical trial landscapes. Key to progressing as a field is collaboration between all stakeholders. The prior disappointing outcomes from the BACEi trials (e.g.,⁹⁷⁻¹⁰⁰) have shown the benefits of working across companies, academia, and health care. This helped to further progress our understanding of compounds, albeit within a setting that was in this instance to uncover the adverse events occurring across these compounds.^{98,99,101} This framework of collaboration was made possible by outside efforts from the Alzheimer's Association, among other stakeholders, and demonstrates the benefits of larger companies working together and sharing data.

Figure 2 summarizes the opportunities, types of data, and processes through which each partner can assist across the landscape of drug development. Although the number and complexity of big data sets are increasing, they can still be utilized to a greater degree and should be addressed across all stakeholder groups to further our understanding of NDs. With large untapped resources within academia, health care, and industry, collaborative efforts and bottom-up expertise are necessary to further advance and apply ML within drug discovery and compound development. Expertise should be engaged earlier and with more frequency in the drug-development process. Teams and individual experts would yield critical knowledge to better improve discovery, selection, and development of new molecular entities. Engaging experts and research groups at the right stage of drug development can also increase the speed of decision-making, enabling quicker progression of compounds, reducing cost, and mitigating overall risk




FIGURE 2 Opportunities for data science and machine learning across clinical development and drug discovery. Data availability ranging from sparse/difficult to obtain (red) to easily obtainable (green).

across compound development. In conclusion, there are vast and varied opportunities for data science and ML to assist drug identification, improve trial design, and increase chances of compound success, all of which are yet to be fully utilized.

AUTHOR CONTRIBUTIONS

All authors contributed to sections of the review related to their areas of expertise. Thomas Doherty, Zhi Yao, and James A. Duce then contributed to drafting and revision of the manuscript. Ahmad A.I. Khleifat and Neil P. Oxtoby supported with further revision of the manuscript for intellectual content. Janice M. Ranson and David J. Llewellyn contributed to the conception of the work, conceived and organized the symposium from which this paper and others in the series originated, edited the manuscript for intellectual content, and harmonized the manuscript with other papers in the series. Ilianna Lourida supported with manuscript harmonization with other papers in the series. All authors have read and approved the final manuscript.

ACKNOWLEDGMENTS

With thanks to collaborators from the Deep Dementia Phenotyping (DEMON) Network State of the Science symposium participants (in alphabetical order): Peter BAGSHAW, Robin BORCHERT, Magda BUCHOLC, James DUCE, Charlotte JAMES, David LLEWELLYN, Donald LYALL, Sarah MARZI, Danielle NEWBY, Neil OXTOBY, Janice RANSON, Tim RITTMAN, Nathan SKENE, Eugene TANG, Michele VELDSMAN, Laura WINCHESTER, and Zhi YAO. This paper was the product of a DEMON Network State of the Science symposium entitled "Harnessing Data Science and AI in Dementia Research" funded by Alzheimer's Research UK. JMR is supported by Alzheimer's Research UK and the Alan Turing Institute/Engineering and Physical Sciences Research Council (EP/N510129/1). DJL is supported by Alzheimer's Research UK, National Institute for Health Research (NIHR) Applied Research Collaboration (ARC) South West Peninsula, National Health and Medical Research Council (NHMRC), National Institute on Aging/National Institutes of Health (RF1AG055654), and the Alan Turing Institute/Engineering and Physical Sciences Research Council (EP/N510129/1). NPO is a UKRI Future Leaders Fellow (MR/S03546X/1) and acknowledges funding from the National Institute for Health Research University College London Hospitals Biomedical Research Centre. AAK is funded by ALS Association Milton Safenowitz Research Fellowship (grant number 22-PDF-609.DOI:10.52546/pc.gr.150909.), The Motor Neurone Disease Association (MNDA) Fellowship (AI Khleifat/Oct21/975-799), The Darby Rimmer Foundation, and The NIHR Maudsley Biomedical Research Centre.

CONFLICT OF INTEREST STATEMENT

TD is an employee of Eisai Europe Ltd. Since participating in this manuscript JAD has become an employee of MSD. All other authors declare no competing interests. Author disclosures are available in the [Supporting Information](#).

CONSENT STATEMENT

Consent for use of human subjects was not necessary for this literature review.

REFERENCES

- Cummings JL, Goldman DP, Simmons-Stern NR, Ponton E. The costs of developing treatments for Alzheimer's disease: a retrospective exploration. *Alzheimers Dement*. 2022;18:469-477.
- DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. *J Health Econ*. 2016;47:20-33.
- Scott TJ, O'Connor AC, Link AN, Beaulieu TJ. Economic analysis of opportunities to accelerate Alzheimer's disease research and development. *Ann N Y Acad Sci*. 2014;1313:17-34.
- Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. *Nat Rev Drug Discov*. 2010;9:203-214.
- Seyhan AA. Lost in translation: the valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles. *Transl Medic Comm*. 2019;4.
- Cummings J. New approaches to symptomatic treatments for Alzheimer's disease. *Mol Neurodegener*. 2021;16.
- van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. *N Engl J Med*. 2023;388:9-21.
- Ceyzeriat K, Zilli T, Millet P, Frisoni GB, Garibotto V, Tournier BB. Learning from the past: a review of clinical trials targeting amyloid, tau and neuroinflammation in Alzheimer's Disease. *Curr Alzheimer Res*. 2020;17:112-125.
- Cummings J, Feldman HH, Scheltens P. The "rights" of precision drug development for Alzheimer's disease. *Alzheimers Res Ther*. 2019;11:76.
- Nag S, Baidya ATK, Mandal A, Mathew AT, Das B, Devi B, et al. Deep learning tools for advancing drug discovery and development. *3 Biotech*. 2022;12:110.
- Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. *Drug Discov Today*. 2021;26:80-93.
- Price DL, Sisodia SS, Borchelt DR. Genetic neurodegenerative diseases: the human illness and transgenic models. *Science*. 1998;282:1079-1083.
- Stephenson D, Hill D, Cedarbaum JM, et al. The qualification of an enrichment biomarker for clinical trials targeting early stages of Parkinson's disease. *J Parkinsons Dis*. 2019;9:825.
- King EA, Davis JW, Degner JF. Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval. *PLoS Genet*. 2019;15:e1008489.
- Carroll C, Tappenden P, Rafia R, et al. Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia: an evidence review group perspective of a NICE single technology appraisal. *Pharmacoeconomics*. 2017;35:537-547.
- Valerio MG, Velayati A, Jain D, Aronow WS. Promising new therapies for the treatment of hypercholesterolemia. *Expert Opin Biol Ther*. 2016;16:609-618.
- Gaspar HA, Breen G. Drug enrichment and discovery from schizophrenia genome-wide association results: an analysis and visualisation approach. *Sci Rep*. 2017;7:12460.
- Zhang B, Gaiteri C, Bodea LG, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. *Cell*. 2013;153:707-720.

19. Huang X, Liu H, Li X, et al. Revealing Alzheimer's disease genes spectrum in the whole-genome by machine learning. *BMC Neurol*. 2018;18:5.
20. Phukan J, Elamin M, Bede P, et al. The syndrome of cognitive impairment in amyotrophic lateral sclerosis: a population-based study. *J Neurol Neurosurg Psychiatry*. 2012;83:102-108.
21. Zhang Y, Wang J, Liu X, Liu H. Exploring the role of RALYL in Alzheimer's disease reserve by network-based approaches. *Alzheimers Res Ther*. 2020;12:165.
22. Tsuji S, Hase T, Yachie-Kinoshita A, et al. Artificial intelligence-based computational framework for drug-target prioritization and inference of novel repositionable drugs for Alzheimer's disease. *Alzheimers Res Ther*. 2021;13:92.
23. Bakkar N, Kovalik T, Lorenzini I, et al. Artificial intelligence in neurodegenerative disease research: use of IBM Watson to identify additional RNA-binding proteins altered in amyotrophic lateral sclerosis. *Acta Neuropathol*. 2018;135:227-247.
24. Carpenter KA, Huang X. Machine learning-based virtual screening and its applications to Alzheimer's drug discovery: a review. *Curr Pharm Des*. 2018;24:3347-3358.
25. Jamal S, Goyal S, Shanker A, Grover A. Checking the STEP-Associated trafficking and internalization of glutamate receptors for reduced cognitive deficits: a machine learning approach-based cheminformatics study and its application for drug repurposing. *PLoS One*. 2015;10:e0129370.
26. Fang J, Li Y, Liu R, et al. Discovery of multitarget-directed ligands against Alzheimer's disease through systematic prediction of chemical-protein interactions. *J Chem Inf Model*. 2015;55:149-164.
27. Ponzoni I, Sebastian-Perez V, Martinez MJ, et al. QSAR classification models for predicting the activity of inhibitors of beta-secretase (BACE1) associated with Alzheimer's. *Disease Sci Rep*. 2019;9:9102.
28. Sebastian-Perez V, Martinez MJ, Gil C, Campillo NE, Martinez A, Ponzoni I. QSAR modelling to identify LRRK2 inhibitors for Parkinson's disease. *J Integr Bioinform*. 2019:16.
29. Vignaux PA, Minerali E, Foil DH, Puhl AC, Ekins S. Machine learning for discovery of GSK3beta inhibitors. *ACS Omega*. 2020;5:26551-26561.
30. Senior AW, Evans R, Jumper J, et al. Improved protein structure prediction using potentials from deep learning. *Nature*. 2020;577:706-710.
31. Kang Y, Leng D, Guo J, Pan L. Sequence-based deep learning antibody design for in silico antibody affinity maturation. arXiv [Preprint]. 2021; Available at: <https://arxiv.org/abs/2103.03724v1>
32. Mason DM, Friedensohn S, Weber CR, et al. Optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning. *Nat Biomed Eng*. 2021;5:600-612.
33. Saka K, Kakuzaki T, Metsugi S, et al. Antibody design using LSTM based deep generative model from phage display library for affinity maturation. *Sci Rep*. 2021;11:5852.
34. Nam Y, Kim M, Chang HS, Shin H. Drug repurposing with network reinforcement. *BMC Bioinf*. 2019;20:383.
35. Park S, Lee DG, Shin H. Network mirroring for drug repositioning. *BMC Med Inform Decis Mak*. 2017;17:55.
36. Hu Y, Zhou G, Zhang C, et al. Identify compounds' target against Alzheimer's disease based on in-silico approach. *Curr Alzheimer Res*. 2019;16:193-208.
37. Rodriguez S, Hug C, Todorov P, et al. Machine learning identifies candidates for drug repurposing in Alzheimer's disease. *Nat Commun*. 2021;12:1033.
38. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Deliv Rev*. 2001;46:3-26.
39. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. *J Med Chem*. 2002;45:2615-2623.
40. Ghose AK, Viswanadhan VN, Wendoloski JJ. A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. *J Comb Chem*. 1999;1:55-68.
41. Gayvert KM, Madhukar NS, Elemento O. A data-driven approach to predicting successes and failures of clinical trials. *Cell Chem Biol*. 2016;23:1294-1301.
42. Brubaker DK, Lauffenburger DA. Translating preclinical models to humans. *Science*. 2020;367:742-743.
43. Ashton NJ, Janelidze S, Al Khleifat A, et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. *Nat Commun*. 2021;12:3400.
44. Min JL, Hemani G, Hannon E, et al. Genomic and phenotypic insights from an atlas of genetic effects on DNA methylation. *Nat Genet*. 2021;53:1311-1321.
45. Bellou E, Stevenson-Hoare J, Escott-Price V. Polygenic risk and pleiotropy in neurodegenerative diseases. *Neurobiol Dis*. 2020;142:104953.
46. Frisoni GB, Altomare D, Thal DR, et al. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. *Nat Rev Neurosci*. 2022;23:53-66.
47. Burrell JR, Halliday GM, Kril JJ, et al. The frontotemporal dementia-motor neuron disease continuum. *Lancet*. 2016;388:919-931.
48. Hagenaars SP, Radakovic R, Crockford C, et al. Genetic risk for neurodegenerative disorders, and its overlap with cognitive ability and physical function. *PLoS One*. 2018;13:e0198187.
49. van Rheenen W, van der Spek RAA, Bakker MK, et al. Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. *Nat Genet*. 2021;53:1636-1648.
50. Brown RH, Jr Al-Chalabi A. Amyotrophic Lateral Sclerosis. *N Engl J Med*. 2017;377:1602.
51. Lill CM, Rengmark A, Pihlstrom L, et al. The role of TREM2 R47H as a risk factor for Alzheimer's disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson's disease. *Alzheimers Dement*. 2015;11:1407-1416.
52. Le Tourneau C, Delord JP, Goncalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. *Lancet Oncol*. 2015;16:1324-1334.
53. Zhang X, Rice M, Tworoger SS, et al. Addition of a polygenic risk score, mammographic density, and endogenous hormones to existing breast cancer risk prediction models: a nested case-control study. *PLoS Med*. 2018;15:e1002644.
54. Frisoni GB, Lathuiliere A. From patients to disease: the difficult case of Alzheimer's. *Lancet Neurol*. 2022;21:105-106.
55. Erdmann J, Kessler T, Munoz Venegas L, Schunkert H. A decade of genome-wide association studies for coronary artery disease: the challenges ahead. *Cardiovasc Res*. 2018;114:1241-1257.
56. Tokamami A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. *Nat Rev Genet*. 2018;19:581-590.
57. McCarthy M, Birney E. Personalized profiles for disease risk must capture all facets of health. *Nature*. 2021;597:175-177.
58. Miller TM, Cudkowicz ME, Genge A, et al. Trial of antisense oligonucleotide tofersen for SOD1 ALS. *N Engl J Med*. 2022;387:1099-1110.
59. Brown CA, Lally C, Kupelian V, Flanders WD. Estimated prevalence and incidence of amyotrophic lateral sclerosis and SOD1 and C9orf72 genetic variants. *Neuroepidemiology*. 2021;55:342-353.
60. Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. *Lancet Neurol*. 2021;20:484-496.

61. Satlin A, Wang J, Logovinsky V, et al. Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease. *Alzheimers Dement (N Y)*. 2016;2:1-12.
62. Ferreira D, Nordberg A, Westman E. Biological subtypes of Alzheimer disease: a systematic review and meta-analysis. *Neurology*. 2020;94:436-448.
63. Young AL, Marinescu RV, Oxtoby NP, et al. Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference. *Nat Commun*. 2018;9:4273.
64. Vogel JW, Young AL, Oxtoby NP, et al. Four distinct trajectories of tau deposition identified in Alzheimer's disease. *Nat Med*. 2021;27:871-881.
65. Collij LE, Salvado G, Wotschel V, et al. Spatial-temporal patterns of beta-amyloid accumulation: a subtype and stage inference model analysis. *Neurology*. 2022;98:e1692.
66. Hampel H, Cummings J, Blennow K, Gao P, Jack CR, Vergallo A. Developing the ATX(N) classification for use across the Alzheimer disease continuum. *Nat Rev Neurol*. 2021;17:580-589.
67. Jack CR, Jr., Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. *Alzheimers Dement*. 2018;14:535-562.
68. Neff RA, Wang M, Vatansever S, et al. Molecular subtyping of Alzheimer's disease using RNA sequencing data reveals novel mechanisms and targets. *Sci Adv*. 2021;7.
69. Tijms BM, Gobom J, Reus L, et al. Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. *Brain*. 2020;143:3776-3792.
70. Wessels AM, Edgar CJ, Nathan PJ, Siemers ER, Maruff P, Harrison J. Cognitive Go/No-Go decision-making criteria in Alzheimer's disease drug development. *Drug Discov Today*. 2021;26:1330-1336.
71. Calvin CM, de Boer C, Raymond V, Gallacher J, Koychev I. European Prevention of Alzheimer's Dementia C. Prediction of Alzheimer's disease biomarker status defined by the 'ATN framework' among cognitively healthy individuals: results from the EPAD longitudinal cohort study. *Alzheimers Res Ther*. 2020;12:143.
72. Ithapu VK, Singh V, Okonkwo OC, et al. Imaging-based enrichment criteria using deep learning algorithms for efficient clinical trials in mild cognitive impairment. *Alzheimers Dement*. 2015;11:1489-1499.
73. Kohannim O, Hua X, Hibar DP, et al. Boosting power for clinical trials using classifiers based on multiple biomarkers. *Neurobiol Aging*. 2010;31:1429-1442.
74. Pilotto A, Imarisio A, Carrarini C, et al. Plasma neurofilament light chain predicts cognitive progression in prodromal and clinical dementia with lewy bodies. *J Alzheimers Dis*. 2021;82:913-919.
75. (U.S.) DoHaHS, (U.S.) FaDA, (U.S.) CfBEaR, (U.S.) CfDEaR. *Enrichment Strategies for Clinical Trials to Support Determination of Effectiveness of Human Drugs and Biological Products Guidance for Industry*. In: (U.S.) DoHaHS, (U.S.) FaDA, (U.S.) CfBEaR, (U.S.) CfDEaR, editors. <http://resource.nlm.nih.gov/101760015>; Silver Spring, MD: Center for Drug Evaluation and Research; 2019.
76. Savelieff MG, Feldman EL. Lessons for clinical trial design in Friedreich's ataxia. *Lancet Neurol*. 2021;20:330-332.
77. Agency EM. Letter of support for Model-based CT enrichment tool for CTs in aMCI. *European Medicines Agency*. 2018. www.ema.europa.eu/contact
78. Schneider P, Walters WP, Plowright AT, et al. Rethinking drug design in the artificial intelligence era. *Nat Rev Drug Discov*. 2020;19:353-364.
79. Shaw DL. Is Open Science the Future of Drug Development? *Yale J Biol Med*. 2017;90:147-151.
80. Ghassemi M, Oakden-Rayner L, Beam AL. The false hope of current approaches to explainable artificial intelligence in health care. *Lancet Digit Health*. 2021;3:e745-e50.
81. Sanchez P, Voisey JP, Xia T, Watson HI, O'Neil AQ, Tsaftaris SA. Causal machine learning for healthcare and precision medicine. *R Soc Open Sci*. 2022;9:220638.
82. Lim J, Walley R, Yuan J, et al. Minimizing patient burden through the use of historical subject-level data in innovative confirmatory clinical trials: review of methods and opportunities. *Ther Innov Regul Sci*. 2018;52:546-559.
83. Ossenkoppele R, Smith R, Mattsson-Carlgrén N, et al. Accuracy of tau positron emission tomography as a prognostic marker in preclinical and prodromal Alzheimer disease: a head-to-head comparison against amyloid positron emission tomography and magnetic resonance imaging. *JAMA Neurol*. 2021;78:961-971.
84. Zetterberg H, Bendlin BB. Biomarkers for Alzheimer's disease: preparing for a new era of disease-modifying therapies. *Mol Psychiatry*. 2021;26:296-308.
85. Eshaghi A, Young AL, Wijeratne PA, et al. Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. *Nat Commun*. 2021;12:2078.
86. Goldacre B, Bardsley M, Benson T, et al. Bringing NHS data analysis into the 21st century. *J R Soc Med*. 2020;113:383-388.
87. He J, Baxter SL, Xu J, Xu J, Zhou X, Zhang K. The practical implementation of artificial intelligence technologies in medicine. *Nat Med*. 2019;25:30-36.
88. Ten Kate M, Ingala S, Schwarz AJ, et al. Secondary prevention of Alzheimer's dementia: neuroimaging contributions. *Alzheimers Res Ther*. 2018;10:112.
89. Aisen PS, Zhou J, Irlizarry MC, et al. AHEAD 3-45 study design: a global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer's disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial). *Alzheimer's Dement*. 2020;16:e044511.
90. (U.S.) FDA. Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD)—Discussion Paper and Request for Feedback. In: (U.S.) FDA, editor. <https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm514737.pdf> 2020.
91. (U.S.) FDA. Artificial Intelligence and Machine Learning in Software as a Medical Device (SaMD) Action Plan. In: (U.S.) FDA, editor. <https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-software-medical-device2021>
92. Agency EM. HMA-EMA Joint Big Data Taskforce-summary report Summary report. In: Agency EM, editor. https://www.ema.europa.eu/en/documents/minutes/hma/ema-joint-task-force-big-data-summary-report_en.pdf2019
93. Agency EM. EMA Regulatory Science to 2025 Strategic reflection. In: Agency EM, editor. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/ema-regulatory-science-2025-strategic-reflection_en.pdf2020
94. Gottesman O, Johansson F, Komorowski M, et al. Guidelines for reinforcement learning in healthcare. *Nat Med*. 2019;25:16-18.
95. Liu X, Cruz Rivera S, Moher D, et al. Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension. *Nat Med*. 2020;26:1364-1374.
96. Siebert J, Joeckel L, Heidrich J. In: Shepperd M, e Abreu FB, da Silva AR, Pérez-Castillo R, eds. *Towards Guidelines for Assessing Qualities of Machine Learning Systems*. Quality of Information and Communications Technology: Springer International Publishing; 2020:17-31. editors.
97. Egan MF, Kost J, Voss T, et al. Randomized trial of verubecestat for prodromal Alzheimer's disease. *N Engl J Med*. 2019;380:1408-1420.
98. Sperling R, Henley D, Aisen PS, et al. Findings of efficacy, safety, and biomarker outcomes of atabecestat in preclinical Alzheimer Dis-

- ease: a truncated randomized phase 2b/3 clinical trial. *JAMA Neurol.* 2021;78:293-301.
99. Sur C, Kost J, Scott D, et al. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer's disease brain. *Brain.* 2020;143:3816-3826.
100. Vormfelde SV, Pezous N, Lefevre G, et al. A pooled analysis of three randomized phase i/ii clinical trials confirms absence of a clinically relevant effect on the QTc Interval by Umibecestat. *Clin Transl Sci.* 2020;13:1316-1326.
101. Wessels AM, Lines C, Stern RA, et al. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease. *Alzheimers Dement.* 2020;16:1483-1492.

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Doherty T, Yao Z, Khleifat AA, et al. Artificial intelligence for dementia drug discovery and trials optimization. *Alzheimer's Dement.* 2023;1-12.
<https://doi.org/10.1002/alz.13428>